Need help finding what you are looking for?
Contact Us
PUBLISHER: QYResearch | PRODUCT CODE: 1867583
PUBLISHER: QYResearch | PRODUCT CODE: 1867583
Microbiome Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
PUBLISHED:
PAGES: 141 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global market for Microbiome Therapeutics was estimated to be worth US$ 568 million in 2024 and is forecast to a readjusted size of US$ 3351 million by 2031 with a CAGR of 30.5% during the forecast period 2025-2031.
Microbiome Therapeutics refers to novel therapeutic approaches that utilize modulation of the human microbiome-especially gut microbiota-to treat or prevent diseases. These therapies include live biotherapeutic products (LBPs), fecal microbiota transplantation (FMT), engineered bacteria, and microbiota-derived metabolites aimed at rebalancing microbial ecosystems. They are being developed for a wide range of conditions, including metabolic disorders, immune dysfunction, neurological diseases, inflammatory bowel disease (IBD), and as adjuncts to cancer immunotherapy. Compared to traditional pharmaceuticals, microbiome-based therapies offer high specificity, personalization, and long-term safety, making them the "fourth therapeutic modality" following small molecules, biologics, and cell/gene therapies.
As the global push for personalized medicine, chronic disease management, and immune-oncology adjunct therapies gains momentum, microbiome therapeutics is entering a critical commercialization window. Regulatory agencies such as the FDA and EMA are streamlining approval pathways for live biotherapeutic products (LBPs), while landmark approvals of Rebyota and Vowst mark a turning point. Strategic alliances between biotech startups and global pharma are accelerating late-stage clinical programs, supported by both capital and platform synergies.
Despite its transformative potential, the microbiome therapeutics sector faces multiple uncertainties. Manufacturing and regulatory frameworks remain inconsistent across countries, slowing clinical translation. Microbiota therapies face inherent variability and complexity, posing challenges in standardizing efficacy and trial design. Technical bottlenecks in sample sourcing, cold-chain logistics, and microbial viability maintenance elevate development costs. Additionally, market education and patient acceptance still require time, particularly in emerging regions like Asia, where applications are largely limited to early-stage R&D and clinical trials.
Demand is expanding beyond gastrointestinal conditions into systemic diseases such as IBD, recurrent Clostridioides difficile infection (CDI), cancer immunotherapy, Parkinson's, and autism spectrum disorders. Partnerships between CROs and pharma are intensifying, while genomics, metabolomics, and AI are enabling high-throughput microbial strain screening. The clinical sector is seeking more reproducible, orally deliverable LBPs and microbiome-derived metabolite products, which align with industrial scalability. With public and private insurers beginning to cover these new modalities, microbiome therapeutics is on the path to becoming a standard pillar of precision medicine.
This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Microbiome Therapeutics by region & country, by Type, and by Application.
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
Market Segmentation
By Company
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Finch Therapeutics
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- Ferring
- C3 Jian
- Rebiotix
- MicroBiome Therapeutics LLC
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Symbiotix Biotherapies
- Vedanta Biosciences
- Metabogen
Segment by Type
- Upper GIT
- Lower GIT
Segment by Application
- C. difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Orphan Drug
- Immuno-oncology
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Microbiome Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Microbiome Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Microbiome Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Microbiome Therapeutics Product Introduction
- 1.2 Global Microbiome Therapeutics Market Size Forecast (2020-2031)
- 1.3 Microbiome Therapeutics Market Trends & Drivers
- 1.3.1 Microbiome Therapeutics Industry Trends
- 1.3.2 Microbiome Therapeutics Market Drivers & Opportunity
- 1.3.3 Microbiome Therapeutics Market Challenges
- 1.3.4 Microbiome Therapeutics Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Microbiome Therapeutics Players Revenue Ranking (2024)
- 2.2 Global Microbiome Therapeutics Revenue by Company (2020-2025)
- 2.3 Key Companies Microbiome Therapeutics Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Microbiome Therapeutics Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Microbiome Therapeutics
- 2.6 Microbiome Therapeutics Market Competitive Analysis
- 2.6.1 Microbiome Therapeutics Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Microbiome Therapeutics Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Therapeutics as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Upper GIT
- 3.1.2 Lower GIT
- 3.2 Global Microbiome Therapeutics Sales Value by Type
- 3.2.1 Global Microbiome Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Microbiome Therapeutics Sales Value, by Type (2020-2031)
- 3.2.3 Global Microbiome Therapeutics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 C. difficile Infection (CDI)
- 4.1.2 Inflammatory Bowel Disease (IBD)
- 4.1.3 Orphan Drug
- 4.1.4 Immuno-oncology
- 4.1.5 Others
- 4.2 Global Microbiome Therapeutics Sales Value by Application
- 4.2.1 Global Microbiome Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Microbiome Therapeutics Sales Value, by Application (2020-2031)
- 4.2.3 Global Microbiome Therapeutics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Microbiome Therapeutics Sales Value by Region
- 5.1.1 Global Microbiome Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Microbiome Therapeutics Sales Value by Region (2020-2025)
- 5.1.3 Global Microbiome Therapeutics Sales Value by Region (2026-2031)
- 5.1.4 Global Microbiome Therapeutics Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Microbiome Therapeutics Sales Value, 2020-2031
- 5.2.2 North America Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Microbiome Therapeutics Sales Value, 2020-2031
- 5.3.2 Europe Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Microbiome Therapeutics Sales Value, 2020-2031
- 5.4.2 Asia Pacific Microbiome Therapeutics Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Microbiome Therapeutics Sales Value, 2020-2031
- 5.5.2 South America Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Microbiome Therapeutics Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Microbiome Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Microbiome Therapeutics Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Microbiome Therapeutics Sales Value, 2020-2031
- 6.3.2 United States Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Microbiome Therapeutics Sales Value, 2020-2031
- 6.4.2 Europe Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Microbiome Therapeutics Sales Value, 2020-2031
- 6.5.2 China Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Microbiome Therapeutics Sales Value, 2020-2031
- 6.6.2 Japan Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Microbiome Therapeutics Sales Value, 2020-2031
- 6.7.2 South Korea Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Microbiome Therapeutics Sales Value, 2020-2031
- 6.8.2 Southeast Asia Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Microbiome Therapeutics Sales Value, 2020-2031
- 6.9.2 India Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Seres Therapeutics
- 7.1.1 Seres Therapeutics Profile
- 7.1.2 Seres Therapeutics Main Business
- 7.1.3 Seres Therapeutics Microbiome Therapeutics Products, Services and Solutions
- 7.1.4 Seres Therapeutics Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.1.5 Seres Therapeutics Recent Developments
- 7.2 Assembly Biosciences
- 7.2.1 Assembly Biosciences Profile
- 7.2.2 Assembly Biosciences Main Business
- 7.2.3 Assembly Biosciences Microbiome Therapeutics Products, Services and Solutions
- 7.2.4 Assembly Biosciences Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.2.5 Assembly Biosciences Recent Developments
- 7.3 Synthetic Biologics
- 7.3.1 Synthetic Biologics Profile
- 7.3.2 Synthetic Biologics Main Business
- 7.3.3 Synthetic Biologics Microbiome Therapeutics Products, Services and Solutions
- 7.3.4 Synthetic Biologics Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.3.5 Synthetic Biologics Recent Developments
- 7.4 Finch Therapeutics
- 7.4.1 Finch Therapeutics Profile
- 7.4.2 Finch Therapeutics Main Business
- 7.4.3 Finch Therapeutics Microbiome Therapeutics Products, Services and Solutions
- 7.4.4 Finch Therapeutics Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.4.5 Finch Therapeutics Recent Developments
- 7.5 PureTech
- 7.5.1 PureTech Profile
- 7.5.2 PureTech Main Business
- 7.5.3 PureTech Microbiome Therapeutics Products, Services and Solutions
- 7.5.4 PureTech Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.5.5 PureTech Recent Developments
- 7.6 Synlogic
- 7.6.1 Synlogic Profile
- 7.6.2 Synlogic Main Business
- 7.6.3 Synlogic Microbiome Therapeutics Products, Services and Solutions
- 7.6.4 Synlogic Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.6.5 Synlogic Recent Developments
- 7.7 Enterome BioScience
- 7.7.1 Enterome BioScience Profile
- 7.7.2 Enterome BioScience Main Business
- 7.7.3 Enterome BioScience Microbiome Therapeutics Products, Services and Solutions
- 7.7.4 Enterome BioScience Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.7.5 Enterome BioScience Recent Developments
- 7.8 4D Pharma
- 7.8.1 4D Pharma Profile
- 7.8.2 4D Pharma Main Business
- 7.8.3 4D Pharma Microbiome Therapeutics Products, Services and Solutions
- 7.8.4 4D Pharma Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.8.5 4D Pharma Recent Developments
- 7.9 Second Genome
- 7.9.1 Second Genome Profile
- 7.9.2 Second Genome Main Business
- 7.9.3 Second Genome Microbiome Therapeutics Products, Services and Solutions
- 7.9.4 Second Genome Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.9.5 Second Genome Recent Developments
- 7.10 Ferring
- 7.10.1 Ferring Profile
- 7.10.2 Ferring Main Business
- 7.10.3 Ferring Microbiome Therapeutics Products, Services and Solutions
- 7.10.4 Ferring Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.10.5 Ferring Recent Developments
- 7.11 C3 Jian
- 7.11.1 C3 Jian Profile
- 7.11.2 C3 Jian Main Business
- 7.11.3 C3 Jian Microbiome Therapeutics Products, Services and Solutions
- 7.11.4 C3 Jian Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.11.5 C3 Jian Recent Developments
- 7.12 Rebiotix
- 7.12.1 Rebiotix Profile
- 7.12.2 Rebiotix Main Business
- 7.12.3 Rebiotix Microbiome Therapeutics Products, Services and Solutions
- 7.12.4 Rebiotix Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.12.5 Rebiotix Recent Developments
- 7.13 MicroBiome Therapeutics LLC
- 7.13.1 MicroBiome Therapeutics LLC Profile
- 7.13.2 MicroBiome Therapeutics LLC Main Business
- 7.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Products, Services and Solutions
- 7.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.13.5 MicroBiome Therapeutics LLC Recent Developments
- 7.14 Metabiomics
- 7.14.1 Metabiomics Profile
- 7.14.2 Metabiomics Main Business
- 7.14.3 Metabiomics Microbiome Therapeutics Products, Services and Solutions
- 7.14.4 Metabiomics Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.14.5 Metabiomics Recent Developments
- 7.15 Ritter Pharmaceuticals
- 7.15.1 Ritter Pharmaceuticals Profile
- 7.15.2 Ritter Pharmaceuticals Main Business
- 7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Products, Services and Solutions
- 7.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.15.5 Ritter Pharmaceuticals Recent Developments
- 7.16 Symberix
- 7.16.1 Symberix Profile
- 7.16.2 Symberix Main Business
- 7.16.3 Symberix Microbiome Therapeutics Products, Services and Solutions
- 7.16.4 Symberix Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.16.5 Symberix Recent Developments
- 7.17 OpenBiome
- 7.17.1 OpenBiome Profile
- 7.17.2 OpenBiome Main Business
- 7.17.3 OpenBiome Microbiome Therapeutics Products, Services and Solutions
- 7.17.4 OpenBiome Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.17.5 OpenBiome Recent Developments
- 7.18 Azitra
- 7.18.1 Azitra Profile
- 7.18.2 Azitra Main Business
- 7.18.3 Azitra Microbiome Therapeutics Products, Services and Solutions
- 7.18.4 Azitra Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.18.5 Azitra Recent Developments
- 7.19 Symbiotix Biotherapies
- 7.19.1 Symbiotix Biotherapies Profile
- 7.19.2 Symbiotix Biotherapies Main Business
- 7.19.3 Symbiotix Biotherapies Microbiome Therapeutics Products, Services and Solutions
- 7.19.4 Symbiotix Biotherapies Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.19.5 Symbiotix Biotherapies Recent Developments
- 7.20 Vedanta Biosciences
- 7.20.1 Vedanta Biosciences Profile
- 7.20.2 Vedanta Biosciences Main Business
- 7.20.3 Vedanta Biosciences Microbiome Therapeutics Products, Services and Solutions
- 7.20.4 Vedanta Biosciences Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.20.5 Vedanta Biosciences Recent Developments
- 7.21 Metabogen
- 7.21.1 Metabogen Profile
- 7.21.2 Metabogen Main Business
- 7.21.3 Metabogen Microbiome Therapeutics Products, Services and Solutions
- 7.21.4 Metabogen Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.21.5 Metabogen Recent Developments
8 Industry Chain Analysis
- 8.1 Microbiome Therapeutics Industrial Chain
- 8.2 Microbiome Therapeutics Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Microbiome Therapeutics Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Microbiome Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
List of Tables
- Table 1. Microbiome Therapeutics Market Trends
- Table 2. Microbiome Therapeutics Market Drivers & Opportunity
- Table 3. Microbiome Therapeutics Market Challenges
- Table 4. Microbiome Therapeutics Market Restraints
- Table 5. Global Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
- Table 6. Global Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
- Table 7. Key Companies Microbiome Therapeutics Manufacturing Base Distribution and Headquarters
- Table 8. Key Companies Microbiome Therapeutics Product Type
- Table 9. Key Companies Time to Begin Mass Production of Microbiome Therapeutics
- Table 10. Global Microbiome Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
- Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Therapeutics as of 2024)
- Table 12. Mergers & Acquisitions, Expansion Plans
- Table 13. Global Microbiome Therapeutics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
- Table 14. Global Microbiome Therapeutics Sales Value by Type (2020-2025) & (US$ Million)
- Table 15. Global Microbiome Therapeutics Sales Value by Type (2026-2031) & (US$ Million)
- Table 16. Global Microbiome Therapeutics Sales Market Share in Value by Type (2020-2025)
- Table 17. Global Microbiome Therapeutics Sales Market Share in Value by Type (2026-2031)
- Table 18. Global Microbiome Therapeutics Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
- Table 19. Global Microbiome Therapeutics Sales Value by Application (2020-2025) & (US$ Million)
- Table 20. Global Microbiome Therapeutics Sales Value by Application (2026-2031) & (US$ Million)
- Table 21. Global Microbiome Therapeutics Sales Market Share in Value by Application (2020-2025)
- Table 22. Global Microbiome Therapeutics Sales Market Share in Value by Application (2026-2031)
- Table 23. Global Microbiome Therapeutics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
- Table 24. Global Microbiome Therapeutics Sales Value by Region (2020-2025) & (US$ Million)
- Table 25. Global Microbiome Therapeutics Sales Value by Region (2026-2031) & (US$ Million)
- Table 26. Global Microbiome Therapeutics Sales Value by Region (2020-2025) & (%)
- Table 27. Global Microbiome Therapeutics Sales Value by Region (2026-2031) & (%)
- Table 28. Key Countries/Regions Microbiome Therapeutics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
- Table 29. Key Countries/Regions Microbiome Therapeutics Sales Value, (2020-2025) & (US$ Million)
- Table 30. Key Countries/Regions Microbiome Therapeutics Sales Value, (2026-2031) & (US$ Million)
- Table 31. Seres Therapeutics Basic Information List
- Table 32. Seres Therapeutics Description and Business Overview
- Table 33. Seres Therapeutics Microbiome Therapeutics Products, Services and Solutions
- Table 34. Revenue (US$ Million) in Microbiome Therapeutics Business of Seres Therapeutics (2020-2025)
- Table 35. Seres Therapeutics Recent Developments
- Table 36. Assembly Biosciences Basic Information List
- Table 37. Assembly Biosciences Description and Business Overview
- Table 38. Assembly Biosciences Microbiome Therapeutics Products, Services and Solutions
- Table 39. Revenue (US$ Million) in Microbiome Therapeutics Business of Assembly Biosciences (2020-2025)
- Table 40. Assembly Biosciences Recent Developments
- Table 41. Synthetic Biologics Basic Information List
- Table 42. Synthetic Biologics Description and Business Overview
- Table 43. Synthetic Biologics Microbiome Therapeutics Products, Services and Solutions
- Table 44. Revenue (US$ Million) in Microbiome Therapeutics Business of Synthetic Biologics (2020-2025)
- Table 45. Synthetic Biologics Recent Developments
- Table 46. Finch Therapeutics Basic Information List
- Table 47. Finch Therapeutics Description and Business Overview
- Table 48. Finch Therapeutics Microbiome Therapeutics Products, Services and Solutions
- Table 49. Revenue (US$ Million) in Microbiome Therapeutics Business of Finch Therapeutics (2020-2025)
- Table 50. Finch Therapeutics Recent Developments
- Table 51. PureTech Basic Information List
- Table 52. PureTech Description and Business Overview
- Table 53. PureTech Microbiome Therapeutics Products, Services and Solutions
- Table 54. Revenue (US$ Million) in Microbiome Therapeutics Business of PureTech (2020-2025)
- Table 55. PureTech Recent Developments
- Table 56. Synlogic Basic Information List
- Table 57. Synlogic Description and Business Overview
- Table 58. Synlogic Microbiome Therapeutics Products, Services and Solutions
- Table 59. Revenue (US$ Million) in Microbiome Therapeutics Business of Synlogic (2020-2025)
- Table 60. Synlogic Recent Developments
- Table 61. Enterome BioScience Basic Information List
- Table 62. Enterome BioScience Description and Business Overview
- Table 63. Enterome BioScience Microbiome Therapeutics Products, Services and Solutions
- Table 64. Revenue (US$ Million) in Microbiome Therapeutics Business of Enterome BioScience (2020-2025)
- Table 65. Enterome BioScience Recent Developments
- Table 66. 4D Pharma Basic Information List
- Table 67. 4D Pharma Description and Business Overview
- Table 68. 4D Pharma Microbiome Therapeutics Products, Services and Solutions
- Table 69. Revenue (US$ Million) in Microbiome Therapeutics Business of 4D Pharma (2020-2025)
- Table 70. 4D Pharma Recent Developments
- Table 71. Second Genome Basic Information List
- Table 72. Second Genome Description and Business Overview
- Table 73. Second Genome Microbiome Therapeutics Products, Services and Solutions
- Table 74. Revenue (US$ Million) in Microbiome Therapeutics Business of Second Genome (2020-2025)
- Table 75. Second Genome Recent Developments
- Table 76. Ferring Basic Information List
- Table 77. Ferring Description and Business Overview
- Table 78. Ferring Microbiome Therapeutics Products, Services and Solutions
- Table 79. Revenue (US$ Million) in Microbiome Therapeutics Business of Ferring (2020-2025)
- Table 80. Ferring Recent Developments
- Table 81. C3 Jian Basic Information List
- Table 82. C3 Jian Description and Business Overview
- Table 83. C3 Jian Microbiome Therapeutics Products, Services and Solutions
- Table 84. Revenue (US$ Million) in Microbiome Therapeutics Business of C3 Jian (2020-2025)
- Table 85. C3 Jian Recent Developments
- Table 86. Rebiotix Basic Information List
- Table 87. Rebiotix Description and Business Overview
- Table 88. Rebiotix Microbiome Therapeutics Products, Services and Solutions
- Table 89. Revenue (US$ Million) in Microbiome Therapeutics Business of Rebiotix (2020-2025)
- Table 90. Rebiotix Recent Developments
- Table 91. MicroBiome Therapeutics LLC Basic Information List
- Table 92. MicroBiome Therapeutics LLC Description and Business Overview
- Table 93. MicroBiome Therapeutics LLC Microbiome Therapeutics Products, Services and Solutions
- Table 94. Revenue (US$ Million) in Microbiome Therapeutics Business of MicroBiome Therapeutics LLC (2020-2025)
- Table 95. MicroBiome Therapeutics LLC Recent Developments
- Table 96. Metabiomics Basic Information List
- Table 97. Metabiomics Description and Business Overview
- Table 98. Metabiomics Microbiome Therapeutics Products, Services and Solutions
- Table 99. Revenue (US$ Million) in Microbiome Therapeutics Business of Metabiomics (2020-2025)
- Table 100. Metabiomics Recent Developments
- Table 101. Ritter Pharmaceuticals Basic Information List
- Table 102. Ritter Pharmaceuticals Description and Business Overview
- Table 103. Ritter Pharmaceuticals Microbiome Therapeutics Products, Services and Solutions
- Table 104. Revenue (US$ Million) in Microbiome Therapeutics Business of Ritter Pharmaceuticals (2020-2025)
- Table 105. Ritter Pharmaceuticals Recent Developments
- Table 106. Symberix Basic Information List
- Table 107. Symberix Description and Business Overview
- Table 108. Symberix Microbiome Therapeutics Products, Services and Solutions
- Table 109. Revenue (US$ Million) in Microbiome Therapeutics Business of Symberix (2020-2025)
- Table 110. Symberix Recent Developments
- Table 111. OpenBiome Basic Information List
- Table 112. OpenBiome Description and Business Overview
- Table 113. OpenBiome Microbiome Therapeutics Products, Services and Solutions
- Table 114. Revenue (US$ Million) in Microbiome Therapeutics Business of OpenBiome (2020-2025)
- Table 115. OpenBiome Recent Developments
- Table 116. Azitra Basic Information List
- Table 117. Azitra Description and Business Overview
- Table 118. Azitra Microbiome Therapeutics Products, Services and Solutions
- Table 119. Revenue (US$ Million) in Microbiome Therapeutics Business of Azitra (2020-2025)
- Table 120. Azitra Recent Developments
- Table 121. Symbiotix Biotherapies Basic Information List
- Table 122. Symbiotix Biotherapies Description and Business Overview
- Table 123. Symbiotix Biotherapies Microbiome Therapeutics Products, Services and Solutions
- Table 124. Revenue (US$ Million) in Microbiome Therapeutics Business of Symbiotix Biotherapies (2020-2025)
- Table 125. Symbiotix Biotherapies Recent Developments
- Table 126. Vedanta Biosciences Basic Information List
- Table 127. Vedanta Biosciences Description and Business Overview
- Table 128. Vedanta Biosciences Microbiome Therapeutics Products, Services and Solutions
- Table 129. Revenue (US$ Million) in Microbiome Therapeutics Business of Vedanta Biosciences (2020-2025)
- Table 130. Vedanta Biosciences Recent Developments
- Table 131. Metabogen Basic Information List
- Table 132. Metabogen Description and Business Overview
- Table 133. Metabogen Microbiome Therapeutics Products, Services and Solutions
- Table 134. Revenue (US$ Million) in Microbiome Therapeutics Business of Metabogen (2020-2025)
- Table 135. Metabogen Recent Developments
- Table 136. Key Raw Materials Lists
- Table 137. Raw Materials Key Suppliers Lists
- Table 138. Microbiome Therapeutics Downstream Customers
- Table 139. Microbiome Therapeutics Distributors List
- Table 140. Research Programs/Design for This Report
- Table 141. Key Data Information from Secondary Sources
- Table 142. Key Data Information from Primary Sources
List of Figures
- Figure 1. Microbiome Therapeutics Product Picture
- Figure 2. Global Microbiome Therapeutics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
- Figure 3. Global Microbiome Therapeutics Sales Value (2020-2031) & (US$ Million)
- Figure 4. Microbiome Therapeutics Report Years Considered
- Figure 5. Global Microbiome Therapeutics Players Revenue Ranking (2024) & (US$ Million)
- Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Microbiome Therapeutics Revenue in 2024
- Figure 7. Microbiome Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 8. Upper GIT Picture
- Figure 9. Lower GIT Picture
- Figure 10. Global Microbiome Therapeutics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 11. Global Microbiome Therapeutics Sales Value Market Share by Type, 2024 & 2031
- Figure 12. Product Picture of C. difficile Infection (CDI)
- Figure 13. Product Picture of Inflammatory Bowel Disease (IBD)
- Figure 14. Product Picture of Orphan Drug
- Figure 15. Product Picture of Immuno-oncology
- Figure 16. Product Picture of Others
- Figure 17. Global Microbiome Therapeutics Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 18. Global Microbiome Therapeutics Sales Value Market Share by Application, 2024 & 2031
- Figure 19. North America Microbiome Therapeutics Sales Value (2020-2031) & (US$ Million)
- Figure 20. North America Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
- Figure 21. Europe Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 22. Europe Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
- Figure 23. Asia Pacific Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 24. Asia Pacific Microbiome Therapeutics Sales Value by Region (%), 2024 VS 2031
- Figure 25. South America Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 26. South America Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
- Figure 27. Middle East & Africa Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 28. Middle East & Africa Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
- Figure 29. Key Countries/Regions Microbiome Therapeutics Sales Value (%), (2020-2031)
- Figure 30. United States Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 31. United States Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 32. United States Microbiome Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 33. Europe Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 34. Europe Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 35. Europe Microbiome Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 36. China Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 37. China Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 38. China Microbiome Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 39. Japan Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 40. Japan Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 41. Japan Microbiome Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 42. South Korea Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 43. South Korea Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 44. South Korea Microbiome Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 45. Southeast Asia Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 46. Southeast Asia Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 47. Southeast Asia Microbiome Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 48. India Microbiome Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 49. India Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 50. India Microbiome Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 51. Microbiome Therapeutics Industrial Chain
- Figure 52. Microbiome Therapeutics Manufacturing Cost Structure
- Figure 53. Channels of Distribution (Direct Sales, and Distribution)
- Figure 54. Bottom-up and Top-down Approaches for This Report
- Figure 55. Data Triangulation
- Figure 56. Key Executives Interviewed
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.